Show simple item record

dc.contributor.authorPlaza Teixeira, Roberto Augusto
dc.contributor.authorOdone-Filho, Vicente
dc.contributor.authorCamargo, Beatriz de
dc.contributor.authorZerbini, Maria Claudia
dc.contributor.authorFillipi, Renne
dc.contributor.authorAlencar, Arlaine
dc.contributor.authorCristofani, Lilian
dc.date.accessioned2016-01-24T14:06:24Z
dc.date.available2016-01-24T14:06:24Z
dc.date.issued2011-04-01
dc.identifierhttp://dx.doi.org/10.3109/08880018.2010.533250
dc.identifier.citationPediatric Hematology and Oncology. London: Informa Healthcare, v. 28, n. 3, p. 194-202, 2011.
dc.identifier.issn0888-0018
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/33629
dc.description.abstractFifteen percent of patients with Wilms'' tumor (WT) experience relapse. It has been suggested that weight and age may affect the chances of relapse. Few studies have investigated the role, if any, between P-glycoprotein (P-gp) and relapse. the authors assessed the prognostic value of tumor weight and age at diagnosis and asked whether some other potential biological markers, specifically P-gp protein expression, had a prognostic value in favorable-histology WT. No association between age and relapse could be found. Patients with tumor weight >= a parts per thousand yen550 g were 6 times more likely to relapse, whereas P-gp expression was positive in 18/40 (45%%) of the patients, of which 10/12 (83.3%%) relapsed and 8/28 (28.6%%) did not. Further studies are necessary to elucidate whether or not P-gp is related to relapse in patients with histologically favorable Wilms'' tumor. If confirmed, the protein may be used in the future as a target for new drugs and treatments for this group of patients.</.en
dc.format.extent194-202
dc.language.isoeng
dc.publisherInforma Healthcare
dc.relation.ispartofPediatric Hematology and Oncology
dc.rightsAcesso restrito
dc.subjectP-glycoproteinen
dc.subjectprognosisen
dc.subjectrecurrenceen
dc.subjecttumor weighten
dc.subjectWilms' tumoren
dc.titleP-Glycoprotein Expression, Tumor Weight, Age, and Relapse in Patients with Stage I and II Favorable-Histology Wilms' Tumoren
dc.typeArtigo
dc.rights.licensehttp://informahealthcare.com/userimages/ContentEditor/1255620309227/Copyright_And_Permissions.pdf
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.description.affiliationHC FMUSP, Inst Crianca, Dept Pediat Oncol & Hematol, São Paulo, Brazil
dc.description.affiliationUniv São Paulo, Inst Crianca, Dept Pediat Oncol & Hematol, Hosp Clin,Fac Med, São Paulo, Brazil
dc.description.affiliationUniv São Paulo, Dept Stat, São Paulo, Brazil
dc.description.affiliationUniv São Paulo, Fac Med, Dept Pathol, São Paulo, Brazil
dc.description.affiliationHosp Canc AC Camargo, Dept Pediat, São Paulo, Brazil
dc.identifier.doi10.3109/08880018.2010.533250
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000288076400004


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record